The conclusion of a Distribution and License Agreement for a gastritis and gastric ulcer treatment drug 'Gaslon N®' in China
On February 15, 2011, Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Shigenobu Maekawa) and Lee’s Pharmaceutical Holdings Ltd. (Headquarters: Hong Kong, China; CEO: Li Xiao Yi) concluded a Distribution and License Agreement for the gastritis and gastric ulcer treatment drug ‘Gaslon N®; Nonproprietary name: Irsogladine Maleate’. Based on this agreement, Nippon Shinyaku granted Lee’s Pharmaceutical Holdings a Distribution and License right for the drug in China.
‘Gaslon N®’ is a gastritis and gastric ulcer treatment drug originally discovered and developed by Nippon Shinyaku as a gastritis and gastric ulcer treatment drug which improves the lesions (erosion, bleeding, redness, edema) in the gastric mucosa caused by acute gastritis and/or acute aggravation stage of chronic gastritis. This drug has been widely used in clinical practice in Japan for over 20 years as one of the major products of Nippon Shinyaku.
Under the Distribution and License Agreement, Lee’s Pharmaceutical Holdings will market and sell this drug to the medical facilities in China. Nippon Shinyaku is to support the marketing activities of Lee’s Pharmaceutical Holdings through various means including academic backup.
Nippon Shinyaku is expecting to boost up its presence by further penetration of ‘Gaslon N®’ in Chinese market and aiming to further expand its business in China.
【Outline of Lee’s Pharmaceutical Holdings Ltd.】
Corporate Name ： Lee’s Pharmaceutical Holdings Limited
Established ： 1994
CEO ： Dr. Li Xiao Yi
Address ： Unit 110-111, Bio Informatics Centre, No. 2 Science Park West
Avenue, Hong Kong Science Park, Shatin, Hong Kong
Employees ： 440 (As of December, 2010)
Sales ： About 2.7 Billion Yen (fiscal 2010)
Business lines ： Manufacture, development and sales of pharmaceuticals and